Literature DB >> 10667183

Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997.

D R Feikin1, A Schuchat, M Kolczak, N L Barrett, L H Harrison, L Lefkowitz, A McGeer, M M Farley, D J Vugia, C Lexau, K R Stefonek, J E Patterson, J H Jorgensen.   

Abstract

OBJECTIVES: This study examined epidemiologic factors affecting mortality from pneumococcal pneumonia in 1995 through 1997.
METHODS: Persons residing in a surveillance area who had community-acquired pneumonia requiring hospitalization and Streptococcus pneumoniae isolated from a sterile site were included in the analysis. Factors affecting mortality were evaluated in univariate and multivariate analyses. The number of deaths from pneumococcal pneumonia requiring hospitalization in the United States in 1996 was estimated.
RESULTS: Of 5837 cases, 12% were fatal. Increased mortality was associated with older age, underlying disease. Asian race, and residence in Toronto/Peel, Ontario. When these factors were controlled for, increased mortality was not associated with resistance to penicillin or cefotaxime. However, when deaths during the first 4 hospital days were excluded, mortality was significantly associated with penicillin minimum inhibitory concentrations of 4.0 or higher and cefotaxime minimum inhibitory concentrations of 2.0 or higher. In 1996, about 7000 to 12,500 deaths occurred in the United States from pneumococcal pneumonia requiring hospitalization.
CONCLUSIONS: Older age and underlying disease remain the most important factors influencing death from pneumococcal pneumonia. Mortality was not elevated in most infections with beta-lactam-resistant pneumococci.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10667183      PMCID: PMC1446155          DOI: 10.2105/ajph.90.2.223

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  39 in total

1.  The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents.

Authors:  S C Redd; G W Rutherford; M A Sande; A R Lifson; W K Hadley; R R Facklam; J S Spika
Journal:  J Infect Dis       Date:  1990-11       Impact factor: 5.226

2.  Decreased susceptibility of penicillin-resistant pneumococci to twenty-four beta-lactam antibiotics.

Authors:  J Liñares; T Alonso; J L Pérez; J Ayats; M A Domínguez; R Pallarés; R Martín
Journal:  J Antimicrob Chemother       Date:  1992-09       Impact factor: 5.790

3.  Effect of increased dosages of amoxicillin in treatment of experimental middle ear otitis due to penicillin-resistant Streptococcus pneumoniae.

Authors:  B Barry; M Muffat-Joly; P Gehanno; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1993-08       Impact factor: 5.191

Review 4.  Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives.

Authors:  E N Janoff; R F Breiman; C L Daley; P C Hopewell
Journal:  Ann Intern Med       Date:  1992-08-15       Impact factor: 25.391

5.  Bacteraemic pneumococcal pneumonia: a continuously evolving disease.

Authors:  T J Marrie
Journal:  J Infect       Date:  1992-05       Impact factor: 6.072

6.  Emergence of drug-resistant pneumococcal infections in the United States.

Authors:  R F Breiman; J C Butler; F C Tenover; J A Elliott; R R Facklam
Journal:  JAMA       Date:  1994-06-15       Impact factor: 56.272

7.  Cephalosporin treatment failure in penicillin- and cephalosporin-resistant Streptococcus pneumoniae meningitis.

Authors:  M M Sloas; F F Barrett; P J Chesney; B K English; B C Hill; F C Tenover; R J Leggiadro
Journal:  Pediatr Infect Dis J       Date:  1992-08       Impact factor: 2.129

8.  In vivo correlates for Streptococcus pneumoniae penicillin resistance in acute otitis media.

Authors:  P Gehanno; G Lenoir; P Berche
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

Review 9.  Management of infections caused by antibiotic-resistant Streptococcus pneumoniae.

Authors:  I R Friedland; G H McCracken
Journal:  N Engl J Med       Date:  1994-08-11       Impact factor: 91.245

10.  Failure of cefotaxime in the treatment of meningitis due to relatively resistant Streptococcus pneumoniae.

Authors:  M J Catalán; J M Fernández; A Vazquez; E Varela de Seijas; A Suárez; J C Bernaldo de Quirós
Journal:  Clin Infect Dis       Date:  1994-05       Impact factor: 9.079

View more
  116 in total

1.  Rapid automated antimicrobial susceptibility testing of Streptococcus pneumoniae by use of the bioMerieux VITEK 2.

Authors:  J H Jorgensen; A L Barry; M M Traczewski; D F Sahm; M L McElmeel; S A Crawford
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

2.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

Review 3.  Limiting the spread of resistant pneumococci: biological and epidemiologic evidence for the effectiveness of alternative interventions.

Authors:  S J Schrag; B Beall; S F Dowell
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

4.  Activities of cethromycin and telithromycin against recent North American isolates of Streptococcus pneumoniae.

Authors:  James H Jorgensen; Sharon A Crawford; M Leticia McElmeel; Cynthia G Whitney
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

5.  The septic shock associated HSPA1B1267 polymorphism influences production of HSPA1A and HSPA1B.

Authors:  Suzanna E L Temple; Karey Y Cheong; Kristin G Ardlie; David Sayer; Grant W Waterer
Journal:  Intensive Care Med       Date:  2004-06-30       Impact factor: 17.440

6.  Impact of penicillin nonsusceptibility on clinical outcomes of patients with nonmeningeal Streptococcus pneumoniae bacteremia in the era of the 2008 clinical and laboratory standards institute penicillin breakpoints.

Authors:  Seong-Ho Choi; Jin-Won Chung; Heungsup Sung; Mi-Na Kim; Sung-Han Kim; Sang-Oh Lee; Yang Soo Kim; Jun Hee Woo; Sang-Ho Choi
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

Review 7.  Role of beta-lactam agents in the treatment of community-acquired pneumonia.

Authors:  J Garau
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-02       Impact factor: 3.267

Review 8.  Optimal therapy for severe pneumococcal community-acquired pneumonia.

Authors:  Manel Luján; Miguel Gallego; Jordi Rello
Journal:  Intensive Care Med       Date:  2006-05-10       Impact factor: 17.440

9.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

10.  In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002.

Authors:  Jeff Powis; Allison McGeer; Karen Green; Otto Vanderkooi; Karl Weiss; George Zhanel; Tony Mazzulli; Magdalena Kuhn; Deirdre Church; Ross Davidson; Kevin Forward; Daryl Hoban; Andrew Simor; Donald E Low
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.